Ocular Hypertension Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

Ocular Hypertension Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com




Ocular Hypertension Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action, route of administration and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

     

Key Topics Covered:

Ocular Hypertension – Overview

Ocular Hypertension – Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Ocular Hypertension – Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Ocular Hypertension – Companies Involved in Therapeutics Development

Ocular Hypertension – Drug Profiles

Ocular Hypertension – Dormant Projects

Ocular Hypertension – Discontinued Products

Ocular Hypertension – Product Development Milestones

Companies Mentioned

  • Aadi Bioscience Inc
  • AbbVie Inc
  • Aerie Pharmaceuticals Inc
  • Angelini Spa
  • Betaliq Inc
  • Chong Kun Dang Pharmaceutical Corp
  • D. Western Therapeutics Institute Inc
  • Future Medicine Co Ltd
  • Glaukos Corp
  • Graybug Vision Inc
  • Ikarovec Ltd
  • Jenivision Inc
  • Kowa Co Ltd
  • Laboratoires Thea SA
  • Laboratorios Sophia SA de CV
  • Lee’s Pharmaceutical Holdings Ltd
  • MediPrint Ophthalmics Inc
  • Neurim Pharmaceuticals Ltd
  • NicOx SA
  • Noveome Biotherapeutics Inc
  • Ocular Therapeutix Inc
  • pH Pharma Co Ltd
  • Qlaris Bio Inc
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Shenzhen Hornetcorn Bio-technology Company Ltd
  • Skye Bioscience Inc
  • Sun Pharma Advanced Research Company Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sustained Nano Systems LLC
  • Sylentis SAU
  • TaeJoon Pharmaceuticals Co Ltd
  • ViSci Ltd
  • Visus Therapeutics Inc
  • Whitecap Biosciences LLC

For more information about this report visit https://www.researchandmarkets.com/r/qgjwpa

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900